Patent: 10,889,630
✉ Email this page to a colleague
Summary for Patent: 10,889,630
| Title: | Method of separating Factor VIII from blood products |
| Abstract: | The invention provides a method for separating a Factor VIII (FVIII) protein from a first composition comprising the FVIII protein, which contains at least the light chain of FVIII, and a von-Willebrand-Factor (vWF) protein which comprises at least the FVIII binding domain of vWF, wherein the FVIII protein can form a complex with the vWF protein, the method comprising the steps: contacting the first composition with an affinity resin comprising a ligand and a matrix, wherein the ligand has an affinity to the light chain of FVIII, and separating the affinity resin from the mixture to obtain a modified first composition and a second composition, wherein the second composition contains the affinity resin, and a complex of the FVIII protein and the vWF protein. |
| Inventor(s): | Stefan Winge, Per Rosen, Alex SCHEEPERS |
| Assignee: | Octapharma AG |
| Application Number: | US16/077,195 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,889,630
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Octapharma Pharmazeutika Produktionsges.m.b.h. | OCTAPLAS | pooled plasma (human), solvent/detergent treated | For Injection | 125416 | January 17, 2013 | ⤷ Start Trial | 2037-02-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,889,630
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017137583 | ⤷ Start Trial |
| United States of America | 2020010532 | ⤷ Start Trial |
| Russian Federation | 2734783 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
